No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AVPT240517C8000
- 0.50
- +0.07+16.28%
15min DelayClose May 9 15:57 ET
0.50High0.50Low
0.50Open0.43Pre Close1 Volume569 Open Interest8.00Strike Price50.00Turnover67.52%IV3.40%PremiumMay 17, 2024Expiry Date0.10Intrinsic Value100Multiplier7DDays to Expiry0.40Time Value100Contract SizeAmericanOptions Type0.5739Delta0.4891Gamma21.60Leverage Ratio-0.0213Theta0.0009Rho12.40Eff Leverage0.0047Vega
Intraday
- 5D
- 1D
News
AvePoint Q1 Loss Narrows, Revenue Rises
AvePoint (AVPT) reported late Thursday a Q1 net loss of $0.01 per diluted share, narrower than the $0.05 loss per share a year earlier. Three analysts polled by Capital IQ expected a $0.05 loss per sh
10-Q: Quarterly report
Express News | AvePoint Expects Q2 Total Revenues Of $73.8M-$75.8M, Est $75.406M
Express News | AvePoint Inc: Sees FY Total Revenues of $314.3 Mln to $320.3 Mln
Express News | AvePoint Inc: Sees Q2 Total Revenues of $73.8 Mln to $75.8 Mln
AvePoint Q1 2024 GAAP EPS $(0.01) Beats $(0.05) Estimate, Sales $74.534M Beat $72.333M Estimate
AvePoint (NASDAQ:AVPT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 80 percent increase over losses of $(0.05) per share
Comments
$AvePoint(AVPT.US$ should have sold this prior to merger 🤣
1
1
Gainers
• $Anaplan(PLAN.US$ +28.2% (to be acquired by Thoma Bravo for $66.00 per share)
• $Guess(GES.US$ +5.04% (entered into an accelerated share repurchase agreement to repurchase $175 mln of its common stock)
• $Membership Collective(MCG.US$ +2.8% (authorizes stock repurchase program to repurchase up to $50 mln of the Company's Class A common stock)
• $Sorrento Therapeutics(SRNE.US$ +2.3% (reports promising results with a universal...
• $Anaplan(PLAN.US$ +28.2% (to be acquired by Thoma Bravo for $66.00 per share)
• $Guess(GES.US$ +5.04% (entered into an accelerated share repurchase agreement to repurchase $175 mln of its common stock)
• $Membership Collective(MCG.US$ +2.8% (authorizes stock repurchase program to repurchase up to $50 mln of the Company's Class A common stock)
• $Sorrento Therapeutics(SRNE.US$ +2.3% (reports promising results with a universal...
19
1
Upgrades
• $Air Products & Chemicals(APD.US$: JPMorgan Upgrades to Overweight from Neutral - PT $275
• $Associated Banc(ASB.US$: Wells Fargo Upgrades to Overweight from Equal Weight - PT $28 (from $26)
• $Armstrong World Industries(AWI.US$: Jefferies Upgrades to Buy from Hold - PT $111 (from $101)
• $BlackBerry(BB.US$: RBC Capital Upgrades to Sector Perform from Underperform - PT $7
• $Commerce Bancshares(CBSH.US$: Wells Fargo Upgrades to Equal Weight from...
• $Air Products & Chemicals(APD.US$: JPMorgan Upgrades to Overweight from Neutral - PT $275
• $Associated Banc(ASB.US$: Wells Fargo Upgrades to Overweight from Equal Weight - PT $28 (from $26)
• $Armstrong World Industries(AWI.US$: Jefferies Upgrades to Buy from Hold - PT $111 (from $101)
• $BlackBerry(BB.US$: RBC Capital Upgrades to Sector Perform from Underperform - PT $7
• $Commerce Bancshares(CBSH.US$: Wells Fargo Upgrades to Equal Weight from...
14
1
$Microsoft(MSFT.US$ $AvePoint(AVPT.US$
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?
13
3
$AvePoint(AVPT.US$ can you get out of reverse now! please, my losses increase daily.
6
1
Read more
Steven J : Who did they merge with?